SCHEMBL4090029

SCHEMBL4090029

CC(C)C(C)NC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 1/20 0.48
FLT3 P36888 3/20 0.47
CNR1 P21554 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 1/20 0.46
ALDH1A1 P00352 4/20 0.46
REV1 Q9UBZ9 1/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP2C19 P33261 1/20 0.44
RORC P51449 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4093212 0.92 KDM4E (0.54) CNR2MAPTKDM4EHSD17B10FLT3
SCHEMBL4094737 0.84 ATM (0.55) CNR2MAPTKDM4EHSD17B10FLT3
SCHEMBL4091289 0.83 CNR2 (0.55) CNR2MAPTKDM4EHSD17B10FLT3
SCHEMBL4086799 0.81 PTPN1 (0.63) MAPTKDM4EHSD17B10FLT3ALDH1A1
SCHEMBL4090439 0.81 CNR2 (0.50) CNR2MAPTKDM4EHSD17B10FLT3
SCHEMBL4085782 0.81 CYP1A2 (0.71) CNR2MAPTKDM4EHSD17B10FLT3
SCHEMBL4090539 0.81 CNR2 (0.59) CNR2MAPTKDM4ECNR1CYP1A2
SCHEMBL4090251 0.79 CNR2 (0.62) CNR2MAPTKDM4EHSD17B10CNR1
SCHEMBL4084167 0.79 CNR2 (0.74) CNR2CNR1CYP1A2CYP2C9ALDH1A1
SCHEMBL4091622 0.79 PTPN1 (0.63) MAPTKDM4EHSD17B10ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885MAPT 2527/4885KDM4E 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.